Aurinia Pharmaceuticals Inc.
AUPH | NASDAQ
$16.71
+$0.10 (+0.60%)
Sep 22, 2026, 11:58 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 283.06M | 235.13M | 175.51M | 134.03M | 45.61M | 50.12M |
Cost of Revenue | 32.67M | 28.25M | 14.15M | 5.66M | 1.09M | n/a |
Gross Profit | 250.39M | 206.89M | 161.37M | 128.37M | 44.51M | 50.12M |
Operating Income | 104.91M | -4.69M | -91.69M | -111.47M | -180.74M | -104.29M |
Interest Income | 13.57M | 16.97M | 17M | 5.12M | 529K | 1.52M |
Pretax Income | 114.16M | 7.45M | -77.47M | -106.35M | -180.21M | -102.77M |
Net Income | 287.2M | 5.75M | -78.02M | -108.18M | -180.97M | -102.68M |
Selling & General & Admin | 101.79M | 172.03M | 195.04M | 196.37M | 171.44M | 97.27M |
Research & Development | 32.51M | 20.79M | 49.64M | 44.99M | 51.14M | 50.33M |
Other Expenses | 11.18M | 18.76M | 8.38M | -1.52M | 2.67M | 6.81M |
Operating Expenses | 145.48M | 211.57M | 253.06M | 239.84M | 225.25M | 154.41M |
Interest Expense | 4.33M | 4.84M | 2.78M | n/a | n/a | n/a |
Selling & Marketing Expenses | 3.21M | 14.09M | n/a | n/a | n/a | n/a |
Cost & Expenses | 178.14M | 239.82M | 267.2M | 245.5M | 226.34M | 154.41M |
Income Tax Expense | -173.05M | 1.7M | 551K | 1.83M | 760K | -94K |
Shares Outstanding (Basic) | 134.37M | 143.06M | 143.24M | 141.92M | 129.37M | 118.47M |
Shares Outstanding (Diluted) | 138.7M | 146.19M | 143.24M | 141.92M | 129.37M | 118.47M |
EPS (Basic) | 2.14 | 0.04 | -0.54 | -0.76 | -1.40 | -0.87 |
EPS (Diluted) | 2.07 | 0.04 | -0.54 | -0.76 | -1.40 | -0.87 |
EBITDA | 127.76M | 31.73M | -63.05M | -103.65M | -177.45M | -102.92M |
EBIT | 118.49M | 12.28M | -74.69M | -106.35M | -180.21M | -104.29M |
Depreciation & Amortization | 9.27M | 19.45M | 11.65M | 2.71M | 2.76M | 1.37M |
Add to Watchlist
Select watchlists to add or remove AUPH